This reference antibody, ponsegromab, targets GDF15 (also known as MIC-1) and is used in research and development for the treatment of cancer-related anorexia and cachexia. It blocks elevated levels of GDF15, a protein linked to inflammation and metabolic dysregulation that causes severe weight loss and reduced appetite in advanced cancer patients. By inhibiting GDF15, it aims to improve appetite, increase body weight, and enhance quality of life. Currently under clinical investigation, it offers potential for stabilizing or reversing cachexia, a condition with few therapeutic options.